Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Operations: 2019-2024

Historic Cash from Operations for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to -$249.1 million.

  • Relay Therapeutics' Cash from Operations rose 17.27% to -$62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.5 million, marking a year-over-year increase of 11.40%. This contributed to the annual value of -$249.1 million for FY2024, which is 17.05% up from last year.
  • Relay Therapeutics' Cash from Operations amounted to -$249.1 million in FY2024, which was up 17.05% from -$300.3 million recorded in FY2023.
  • Relay Therapeutics' 5-year Cash from Operations high stood at -$74.4 million for FY2021, and its period low was -$300.3 million during FY2023.
  • In the last 3 years, Relay Therapeutics' Cash from Operations had a median value of -$249.1 million in 2024 and averaged -$259.6 million.
  • In the last 5 years, Relay Therapeutics' Cash from Operations grew by 27.40% in 2021 and then tumbled by 208.43% in 2022.
  • Yearly analysis of 5 years shows Relay Therapeutics' Cash from Operations stood at -$102.5 million in 2020, then rose by 27.40% to -$74.4 million in 2021, then tumbled by 208.43% to -$229.5 million in 2022, then plummeted by 30.86% to -$300.3 million in 2023, then climbed by 17.05% to -$249.1 million in 2024.